|
|
【TMCLIFE 0101 交流专区】TMC生命科学
[复制链接]
|
|
|
发表于 1-10-2014 03:16 AM
|
显示全部楼层
| 1. Details of Corporate Proposal | Whether the corporate proposal involves the issuance of new type
and new class of securities? | No | Types of corporate proposal | Others | Details of corporate proposal | Conversion of Warrants to Ordinary Shares | No. of shares issued under this corporate proposal | 10,020,000 | Issue price per share ($$) | MYR 0.400 | Par Value ($$) | MYR 0.100 | | Latest issued and paid up share capital after the above corporate proposal in the following | Units | 812,492,360 | Currency | MYR 81,249,236.000 | Listing Date | 01/10/2014 |
|
|
|
|
|
|
|
|
|
|
|
|
发表于 25-10-2014 12:50 PM
|
显示全部楼层
TMC 生命科学首季转盈
财经新闻 财经 2014-10-25 11:00
http://www.nanyang.com/node/657748?tid=462
（吉隆坡24日讯）TMC生命科学（TMCLIFE，0101，主板贸服股）截至8月31日首季转亏为盈，取得72万8000令吉净利，或每股0.09仙。
根据文告，该公司去年同期面对36万8000令吉的净亏，或每股0.05仙。
归功于增加床位和招募更多医生，首季营业额也从1880万7000令吉，年增23.21%，达2317万2000令吉，进而带动净利表现。
另一方面，TMC生命科学已向马交所申请，将提高公众持股比例的期限，延长6个月至明年3月18日。
截至本月中，公众持股比例仅为24.28%，依旧不符合条例。
早前提出全购的新加坡亿万富豪林荣富旗下Sasteria公司，正探讨符合当前市况的计划，以提高此比例。
SUMMARY OF KEY FINANCIAL INFORMATION
31/08/2014 |
| | INDIVIDUAL PERIOD | CUMULATIVE PERIOD | CURRENT YEAR QUARTER | PRECEDING YEAR
CORRESPONDING
QUARTER | CURRENT YEAR TO DATE | PRECEDING YEAR
CORRESPONDING
PERIOD | 31/08/2014 | 31/08/2013 | 31/08/2014 | 31/08/2013 | $$'000 | $$'000 | $$'000 | $$'000 |
| 1 | Revenue | 23,172 | 18,807 | 23,172 | 18,807 | | 2 | Profit/(loss) before tax | 643 | -316 | 643 | -316 | | 3 | Profit/(loss) for the period | 728 | -368 | 728 | -368 | | 4 | Profit/(loss) attributable to ordinary equity holders of the parent | 728 | -368 | 728 | -368 | | 5 | Basic earnings/(loss) per share (Subunit) | 0.09 | -0.05 | 0.09 | -0.05 | | 6 | Proposed/Declared dividend per share (Subunit) | 0.00 | 0.00 | 0.00 | 0.00 |
|
| AS AT END OF CURRENT QUARTER | AS AT PRECEDING FINANCIAL YEAR END | 7
| Net assets per share attributable to ordinary equity holders of the parent ($$) | 0.1700 | 0.1700 |
本帖最后由 icy97 于 28-10-2014 06:00 AM 编辑
|
|
|
|
|
|
|
|
|
|
|
|
发表于 29-10-2014 04:36 AM
|
显示全部楼层
改建病房增加床位 TMC生命科学拓商机
二零一四年十月二十七日 晚上七时五十八分
（吉隆坡27日讯）TMC生命科学有限公司（TMCLIFE，0101，创业板）预测，随着把其旗舰医院丽阳医疗中心（Tropicana Medical Centre）第7层转换为病房后，其病床床位将在未来12个月内增加40%。
集团首席执行员黄长彦医生说，约700万至800万令吉已经拨作设立新病房用途。
他指出：“除此之外，这个数额也将包括翻新我们的洗肾中心。”
据该集团2014常年报告显示，新病房预料将在截至2016年5月31日止财政年完成。
黄长彦补充，该集团也探讨扩大该医院意外与急症部门产能的可能性，同时该集团在上述医院基础增设的诊所也将于未来2至3个月开始营运。
“我们首先将扩大最大的空间，然后才放眼外部扩充。当然我们不排除合并与收购活动，我们随时都开始商机。如果出现合适机会，我们将会落实。”
展望未来，黄长彦称，该集团的前景明朗，但消费税所带来的不稳定影响仍然笼罩。
“消费税对我们经营的影响仍有待观察。这将是整个行业的问题。”【光华日报财经】 |
|
|
|
|
|
|
|
|
|
|
|
发表于 19-11-2014 04:52 AM
|
显示全部楼层
Expiry/Maturity of the securities
Type of Securities | Warrants | Type of Expiry | Expiry/Maturity of the securities | Mode of Satisfaction of Exercise/Conversion Price | Tendering of securities | Exercise/Strike/Conversion Price | MYR 0.4000 | Exercise/ Conversion Ratio | 1:1 | Settlement Type/ Convertible into | Physical (Shares) | Last Date & Time for Trading | 04/12/2014 05:00 PM | Date & Time of Suspension | 05/12/2014 09:00 AM | Last Date & Time for Transfer into Depositor's CDS a/c | 15/12/2014 04:00 PM | Date & Time of Expiry | 22/12/2014 05:00 PM | Date & Time of Delisting | 23/12/2014 09:00 AM |
Announcement Info| Company Name | TMC LIFE SCIENCES BERHAD | | Stock Name | TMCLIFE-WA | | Date Announced | 18 Nov 2014 | | Category | Expiry / Maturity / Termination of Securities | | Reference No | CA-141114-33638 |
|
|
|
|
|
|
|
|
|
|
|
|
发表于 26-12-2014 04:07 AM
|
显示全部楼层
Whether the corporate proposal involves the issuance of new type
and new class of securities? | No | Types of corporate proposal | Others | Details of corporate proposal | Conversion of Warrants to Ordinary Shares | No. of shares issued under this corporate proposal | 233,675,366 | Issue price per share ($$) | MYR 0.400 | Par Value ($$) | MYR 0.100 | | Latest issued and paid up share capital after the above corporate proposal in the following | Units | 1,192,644,737 | Currency | MYR 119,264,473.700 | Listing Date | 26/12/2014 |
|
|
|
|
|
|
|
|
|
|
|
|
发表于 26-12-2014 04:10 AM
|
显示全部楼层
Name | Sasteria (M) Pte. Ltd. | Address | 101 Thomson Road
#14-02/03
United Square
Singapore (307591) | NRIC/Passport No/Company No. | 201421357N | Nationality/Country of incorporation | Singapore | Descriptions (Class & nominal value) | Ordinary share of RM0.10 each | Name & address of registered holder | Maybank Nominees (Asing) Sdn. Bhd.
14th Floor, Menara Maybank
100 Jalan Tun Perak
50050 Kuala Lumpur |
Details of changesCurrency: Malaysian Ringgit (MYR) | Type of transaction | Date of change | No of securities | Price Transacted (RM) | | Acquired | 23/12/2014 | 206,867,950 |
|
Circumstances by reason of which change has occurred | Exercise of Warrants to subscribe for new ordinary shares | Nature of interest | Direct interest | Direct (units) |
| | Direct (%) |
| | Indirect/deemed interest (units) |
| | Indirect/deemed interest (%) |
| | Total no of securities after change | 821,304,822 | Date of notice | 24/12/2014
|
|
|
|
|
|
|
|
|
|
|
|
|
发表于 15-1-2015 01:56 PM
|
显示全部楼层
本帖最后由 icy97 于 15-1-2015 08:50 PM 编辑
TMC擴展麗陽醫療中心 首階段成本2.5億至3億
財經企業14 Jan 2015 21:06
（吉隆坡14日訊）TMC（TMCLIFE，0101，主要板貿服）計劃擴展旗下位于哥打白沙羅的旗艦醫院麗陽醫療中心（Tropicana Medical Centre），首階段擴展總成本估計為2.5億令吉至3億令吉。
TMC今日向馬證交所報備，首階段擴展成本估計為2.5億至3億令吉，包括建造一棟新建築物以及其他設備和配件等資本開銷。
該公司計劃通過公司擁有的現金和銀行盈余資金來籌措首階段擴展計劃費用，截至去年12月底，公司擁有的現金和銀行盈余達1億9080萬令吉。
根據報備文件指出，麗陽醫療中心位于哥打白沙羅，由麗陽醫療中心大馬私人有限公司持有，土地面積達6英畝，截至目前為止，只有21%土地被利用。鑒于市場對醫療服務需求維持強勁，該中心目前正在擴展新病床，完成后將會增至190張。
隨著醫療服務需求強勁，因此公司希望進一步擴大麗陽醫療中心，成為巴生谷最大的綜合性醫療健保中心。
另外，TMC發另一文告指出，在2011年12月22日發行的憑單，已在去年12月22日截止，總發行量4億118萬6500單位，其中98.99%或1億5890萬令吉已轉換成股票。
目前，該公司繳足資本達1億1990萬令吉或11億9952萬1436股。【中国报财经】
Type | Announcement | Subject | OTHERS | Description | TMC LIFE SCIENCES BERHAD
PROPOSED EXPANSION PLAN AT TROPICANA MEDICAL CENTRE, KOTA DAMANSARA | 1. INTRODUCTION The Board of Directors of TMC Life Sciences Berhad (“TMC” or “Company”) wishes to announce that the Group plans to expand the facilities at its flagship hospital, Tropicana Medical Centre at Kota Damansara (“Proposed Expansion Plan”).
2. PROPOSED EXPANSION PLAN Tropicana Medical Centre is currently operating at its premises erected on the 6 acres of land owned by Tropicana Medical Centre (M) Sdn Bhd (a wholly-owned subsidiary of TMC) located at Kota Damansara. The 6 acres of land can be converted to a maximum gross floor area (“GFA”) of approximately 1.1 million square feet (“sf”). To-date, only about 21% of the maximum GFA has been utilized and occupied by the current Tropicana Medical Centre.
Demand for the medical services of Tropicana Medical Centre remains strong and it is now undertaking the renovations to increase its inpatient bed capacity by another 51 beds. When these renovations are completed, Tropicana Medical Centre will then have 190 inpatient beds. With the continuous strong demand for quality healthcare, the Group plans to expand Tropicana Medical Centre to become one of the largest integrated healthcare campus in the Klang Valley.
The first phase of the Proposed Expansion Plan, subject to regulatory approval, which would involve the construction of a new block of building on 2.4 acres of the land, to house another 180 inpatient beds, 128,000 sf of specialist outpatient clinics, 5 additional operating theatres and 170,000 sf of commercial/retail space. The commercial/retail space will focus on offering healthcare products and services that patients will need. (“First Phase Proposed Expansion”)
When the First Phase Proposed Expansion is completed, Tropicana Medical Centre will have 410 inpatient beds (includes additional 40 beds to be installed at existing building after relocation of certain facilities to the new building), 10 operating theatres and some 140,000 sf of space dedicated to outpatient services, offering comprehensive tertiary healthcare services, including one of the largest private IVF centres in South East Asia.
After the completion of the First Phase Proposed Expansion, there would be subsequent phase to expand on the balance of the land. It is envisaged that, when the expansion plans on the whole 6 acres of land are fully completed, the entire integrated healthcare campus will host 550 acute hospital beds and another 100 long- stay beds or service apartments to serve patients families and patients who need some form of care post-discharge from the acute general hospital. Specialist outpatient clinics or suites will occupy a total floor area of 300,000 to 400,000 sf. The entire integrated healthcare campus will serve not just patients from the Klang Valley, but also patients from the whole Malaysia and the region.
The Group intends to look at expansion beyond the planned integrated healthcare campus at Kota Damansara.
3. FIRST PHASE PROPOSED EXPANSION COST AND MODE OF FINANCING The total cost for the First Phase Proposed Expansion is expected to be in the region of RM250 million to RM300 million, which includes the construction on the new building and other capital expenditure on equipment and fittings.
The Group intends to finance the First Phase Proposed Expansion via existing cash and bank balances and surplus of cash from existing operations. The cash and bank balances stood at RM190.8 million as at 31 December 2014, after the conversion of 397.1 million warrants which netted the conversion proceeds of RM158.9 million. The warrants had since expired on 22 December 2014.
4. TIME FRAME FOR THE FIRST PHASE PROPOSED EXPANSION The First Phase Proposed Expansion is expected to commence in the first half of 2016 and it will take approximately 4 years to complete.
5. EFFECTS OF THE FIRST PHASE PROPOSED EXPANSION 5.1 Share Capital and Substantial Shareholder’s Shareholding The financing for the First Phase Proposed Expansion does not involve any issuance of new shares in the Company and therefore will not have any effect on the share capital and substantial shareholder’s shareholding.
5.2 Earnings and Earnings Per Share The First Phase Proposed Expansion is not expected to have a material impact on the earnings or earnings per share of TMC for the financial year ending 31 May 2015. However, it is expected to enhance the earnings of the Group in the future years.
5.3 Gearing As the First Phase Proposed Expansion is to be funded entirely from existing cash and bank balances and surplus funds to be generated from the existing operation, there would be no impact to total gearing of the Group.
6. DIRECTORS' AND MAJOR SHAREHOLDERS' INTEREST None of the Directors and/or major shareholders of TMC and/or persons connected to them, has any interest, direct or indirect, in the First Phase Proposed Expansion.
7. STATEMENT BY THE DIRECTORS The Board of Directors of TMC, having taken into consideration all aspects of the Proposed Expansion, is of the opinion that the Proposed Expansion would be in the best interest of TMC Group.
8. APPROVALS REQUIRED The Proposed Expansion is not subject to the approval of the shareholders.
A press release in relation to the above proposed expansion plan is attached for information.
This announcement is dated 14 January 2015.
http://www.bursamalaysia.com/market/listed-companies/company-announcements/1851857 |
|
|
|
|
|
|
|
|
|
|
|
|
发表于 23-1-2015 04:54 AM
|
显示全部楼层
本帖最后由 icy97 于 25-1-2015 02:33 AM 编辑
TMC生科次季少赚3.9%
财经新闻 财经 2015-01-24 11:20
（吉隆坡23日讯）员工成本上涨，TMC生命科学（TMCLIFE，0101，主板贸服股）次季净利按年下跌3.9%至230万7000令吉。
不过，营业额则因床位增加可容纳更多病人，按年增12.9%至2510万1000令吉。
在上半年，公司净利按年增49%至303万5000令吉，营业额则累积至4827万3000令吉，起17.6%。
尽管令吉贬值会导致进口药物成本上涨，该公司对保健业前景保持正面看法。【南洋网财经】
SUMMARY OF KEY FINANCIAL INFORMATION
30/11/2014 |
| | INDIVIDUAL PERIOD | CUMULATIVE PERIOD | CURRENT YEAR QUARTER | PRECEDING YEAR
CORRESPONDING
QUARTER | CURRENT YEAR TO DATE | PRECEDING YEAR
CORRESPONDING
PERIOD | 30/11/2014 | 30/11/2013 | 30/11/2014 | 30/11/2013 | $$'000 | $$'000 | $$'000 | $$'000 |
| 1 | Revenue | 25,101 | 22,220 | 48,273 | 41,027 | | 2 | Profit/(loss) before tax | 2,121 | 2,513 | 2,765 | 2,197 | | 3 | Profit/(loss) for the period | 2,307 | 2,401 | 3,035 | 2,033 | | 4 | Profit/(loss) attributable to ordinary equity holders of the parent | 2,307 | 2,401 | 3,035 | 2,033 | | 5 | Basic earnings/(loss) per share (Subunit) | 0.28 | 0.30 | 0.37 | 0.25 | | 6 | Proposed/Declared dividend per share (Subunit) | 0.00 | 0.00 | 0.00 | 0.00 |
|
| AS AT END OF CURRENT QUARTER | AS AT PRECEDING FINANCIAL YEAR END | 7
| Net assets per share attributable to ordinary equity holders of the parent ($$) | 0.1900 | 0.1700 |
|
|
|
|
|
|
|
|
|
|
|
|
发表于 6-2-2015 11:23 PM
|
显示全部楼层
本帖最后由 icy97 于 7-2-2015 11:10 PM 编辑
TMC 生科斥4亿 买新山汤森医药中心
财经新闻 财经 2015-02-07 10:28
（吉隆坡6日讯）TMC生命科学（TMCLIFE，0101，主板贸服股）建议以4亿令吉，收购新山的汤森医药中心（Thomson Medical Hub），以将公司打造为国内主要保健业者。
该公司今日向马交所报备，已与BestBlend私人有限公司签约，收购旗下BBWaterfront私人有限公司全数股权。
BB Waterfront拥有一项名为依斯干达汤森（Thomson Iskandar）的医药中心工程，已获准在面积达1.6公顷的土地上，建立Iskandariah医院。
Iskandariah医院已获准设置272个床位，未来还有发展空间，增加床位到500个。该计划还包括一个门诊医疗中心，有400个诊所。
该医院将由新加坡著名的医院营运业者汤森医药（Thomson Medical）集团经营。
TMC生命科学相信，与汤森医药合作，加上靠近新加坡，策略性位置料可吸引更多新加坡病人，前来寻求可负担的专科医药服务。
该公司也认为，这是将业务版图拓展到巴生谷以外的好时机，并展望旗下所经营的医院床位，可增加到1000个。
资产属于大股东
TMC生命科学的大股东，是新加坡亿万富豪林荣富，而他同时也持有Best Blend的70%股权。
TMC生命科学以发售5亿3333万3333股新股，给Best Blend的方式，完成上述收购活动。
每股发售价为75仙，同时也配送2亿6666万6666单位免费凭单。
完成该项收购活动后，TMC生命科学也将以2配1的方式，派送5亿9976万718单位免费凭单给该公司现有股东作为回馈。
2项凭单的行使价皆为75仙，行使期限为4年。【南洋网财经】
Type | Announcement | Subject | TRANSACTIONS (CHAPTER 10 OF LISTING REQUIREMENTS)
RELATED PARTY TRANSACTIONS | Description | TMC LIFE SCIENCES BERHAD (“TMC” OR “COMPANY”)
(I) PROPOSED ACQUISITION OF 1,000,000 ORDINARY SHARES OF RM1.00 EACH, REPRESENTING THE ENTIRE EQUITY INTEREST OF BB WATERFRONT SDN. BHD. (“BB WATERFRONT”) FOR A PURCHASE CONSIDERATION OF RM400.0 MILLION TO BE SATISFIED VIA THE ISSUANCE OF 533,333,333 NEW ORDINARY SHARES OF RM0.10 EACH IN TMC (“SHARES” OR “TMC SHARES”) AT AN ISSUE PRICE OF RM0.75 PER SHARE, TOGETHER WITH 266,666,666 FREE DETACHABLE WARRANTS (“WARRANTS”) ON THE BASIS OF ONE (1) FREE WARRANT FOR EVERY TWO (2) TMC SHARES (“PROPOSED ACQUISITION”);
(II) PROPOSED BONUS ISSUE OF 599,760,718 WARRANTS IN TMC TO ALL ENTITLED SHAREHOLDERS OF THE COMPANY ON THE BASIS OF ONE (1) WARRANT FOR EVERY TWO (2) EXISTING TMC SHARES HELD AT AN ENTITLEMENT DATE TO BE DETERMINED LATER (“ENTITLEMENT DATE”) (“PROPOSED BONUS ISSUE OF WARRANTS”); AND
(III) PROPOSED INCREASE IN THE AUTHORISED SHARE CAPITAL OF TMC FROM RM200,000,000 COMPRISING 2,000,000,000 SHARES TO RM500,000,000 COMPRISING 5,000,000,000 SHARES AND IN CONSEQUENCE THEREOF, THE COMPANY’S MEMORANDUM OF ASSOCIATION (“M&A”) BE ALTERED ACCORDINGLY (“PROPOSED IASC”)
| On behalf of the Board of Directors of the Company, Maybank Investment Bank Berhad wishes to announce that the Company has today entered into a share sale and purchase agreement with Best Blend Sdn. Bhd. for the Proposed Acquisition.
In addition, the Company is also proposing to undertake the Proposed Bonus Issue of Warrants and Proposed IASC.
Please refer to the attachment for further details of the Proposals . A press release in relation to the Proposals is also attached.
This announcement is dated 6 February 2015.
http://www.bursamalaysia.com/market/listed-companies/company-announcements/1871125 |
|
|
|
|
|
|
|
|
|
|
|
|
发表于 15-2-2015 05:03 AM
|
显示全部楼层
本帖最后由 icy97 于 4-3-2015 03:10 AM 编辑
TMC生命科学大股东 欲打造医疗旅游业
二零一五年三月一日 晚上六时三十九分
拥有一座医疗中心和一间生育中心的私人保健经营商TMC生命科学有限公司（TMCLIFE，0101，创业板），正准备大展拳脚。大股东林荣福有意转型该公司，在未来4年内打造一个为医疗旅游领域主要业者。
建议中悉数透过发行新股支付，耗资4亿令吉收购林荣福投资工具Best Blend海滨私人有限公司，将铺路发展在柔佛依斯干达区的康生依斯干达医疗中枢。
该医疗中枢将由新加坡康生医疗集团子公司康生国际管理，将拥有一间272病床医院，称为Iskandariah医院，以及一个有约400间诊所套房的门诊医疗中心。
与此同时，TMC生命科学也对其现有医院丽阳医疗中心展开第一期扩建，预料耗资约3亿令吉。这将看到其住院病床由数量目前的139张，增加3倍到410张。
这些扩充计划显示着其雄心，也是艰辛时期所必须做的。
对一家在截至2014年5月31日止最新财政年仅录得646万令吉净盈利的公司而言，该集团面对保健领域漫长孕育期和激烈竞争的双重冲击。
举例而言，市值达到40亿令吉，经营25间私人专科医院，并且每年带来数十亿令吉收益的柔佛医药保健有限公司（KPJ，5878，贸易服务组），目前仅以26倍市盈率水平交易。比较之下，旗下只有2间医疗中心，2014财政年录得收益8813万令吉的TMC生命科学，却达到76倍市盈率，可能是由于林荣福注入保健资产的行动所带动。
另一方面，若进军依斯干达区医疗旅游证明成功，该集团预期来年不俗的收益成长。
TMC生命科学集团首席财务员叶荣义（译音）表示，Iskandariah医院的建筑工程将在4年内完成。
“建议中计划的建筑将在2015年杪展开，并预期可在2018年杪建竣。不过，康生依斯干达则将从2016年开始，透过出售诊所套房贡献收益。”
该集团的股价今年逐步走高，迄今已录得25%的涨幅。这个趋势局部是由于以每股75仙发行股票融资收购Best Blend海滨，上述出价相等于TMC生命科学执行买卖协议前最后成交价64仙，溢价达17.2%。
林荣福控制Best Blend海滨的70%股权，而柔佛王储东姑依斯迈则拥有其余30%。
虽然融资上述交易的每股75仙发行价，写下TMC生命科学历史最高股价，但Best Blend海滨确实拥有吸引的价值。
继脱售位于依斯干达区的3项地产，引入庞大现金来源以着手上述康生依斯干达计划后，Best Blend海滨在截至2014年3月31日止财政年创下7亿3660万令吉。
该集团指出，上述计划的预测发展成本为9亿令吉，而另外3亿令吉则将拨作固定资产投资，包括医疗设备。
叶荣义称：“我们对康生依斯干达的强大潜质有信心，它将成为集团的一个重大收益贡献者。Iskandariah医院则将在2018年开始经营。”
保健领域将在今年面对数个逆风。在早前的报告中，达证券研究指出，4月起实施消费税，可能促使私人保健经营商的投入成本提高4%。
惟叶氏认为：“集团将不会因为消费税实施而面对重大的负面影响。”
另一个问题是新医院传统上面对3至5年的孕育期，意味着期间TMC生命科学将须仰赖其门诊套房销售。
不过，随着集团完成丽阳医疗中心的首期扩建，以及从康生依斯干达获得贡献后，整体收益将看到大幅的提升。【光华日报财经】 |
|
|
|
|
|
|
|
|
|
|
|
发表于 17-2-2015 05:34 AM
|
显示全部楼层
Type | Announcement | Subject | NEW ISSUE OF SECURITIES (CHAPTER 6 OF LISTING REQUIREMENTS)
ESOS | Description | TMC LIFE SCIENCES BERHAD (“TMC” OR “COMPANY”)
PROPOSED ESTABLISHMENT OF AN EMPLOYEES’ SHARE OPTION SCHEME OF UP TO FIFTEEN PERCENT (15%) OF THE ISSUED AND PAID-UP SHARE CAPITAL (EXCLUDING TREASURY SHARES) OF THE COMPANY (“PROPOSED ESOS”) | |
|
|
|
|
|
|
|
|
|
|
|
|
发表于 25-3-2015 02:58 AM
|
显示全部楼层
Date of change | 24/03/2015 | Name | Dr. Chan Boon Kheng | Age | 47 | Nationality | Singaporean | Type of change | Redesignation | Previous Position | Non-Executive Director | New Position | Executive Director | Directorate | Executive | Qualifications | Medical Degree from National University of Singapore.
MBA (Honors) from University of Chicago. | Working experience and occupation | Dr. Chan was an Advisor and Interim Group Chief Executive Officer of Pantai Holdings Berhad ("Pantai") during 2007-2010. He also served as an Advisor to various healthcare companies in Malaysia including Mudabala Development Company based in Abu Dhabi and was the Chief Executive Officer and General Manager of East Shore Hospital in Singapore under Parkway Healthcare prior to joining Pantai.
Dr. Chan is the Chairman of Innoheart, a pre-clinical Contract Research Organisation based in Singapore. He is also currently a director of healthcare consultancy companies whose activities ranges from transition management, process improvement, performance management and commercialising bioscience and technology applications. |
|
|
|
|
|
|
|
|
|
|
|
|
发表于 24-4-2015 12:22 AM
|
显示全部楼层
本帖最后由 icy97 于 24-4-2015 03:55 AM 编辑
TMC生科第三季净利扬67%
财经新闻 财经 2015-04-23 07:22
（吉隆坡22日讯）病人增加，推动TMC生命科学（TMCLIFE，0101，主板贸服股）截至2月28日第三季净利扬66.7%，达290万6000令吉；同期营业额起21.6%，报2641万1000令吉。
累计首3季，净利增长57.3%，至594万1000令吉；营业额扩大19%，报7468万4000令吉。
TMC生命科学表示，营业额表现归功于病人人数走高，而公司早前也已增加病床数量，及聘请更多咨询顾问来迎合需求。
“虽然营运开销走高，但凭着较高的营业额和利息收入，我们仍录得较高税前盈利。”【南洋网财经】
SUMMARY OF KEY FINANCIAL INFORMATION
28 Feb 2015 |
| | INDIVIDUAL PERIOD | CUMULATIVE PERIOD | CURRENT YEAR QUARTER | PRECEDING YEAR
CORRESPONDING
QUARTER | CURRENT YEAR TO DATE | PRECEDING YEAR
CORRESPONDING
PERIOD | 28 Feb 2015 | 28 Feb 2014 | 28 Feb 2015 | 28 Feb 2014 | $$'000 | $$'000 | $$'000 | $$'000 |
| 1 | Revenue | 26,411 | 21,715 | 74,684 | 62,742 | | 2 | Profit/(loss) before tax | 3,196 | 1,740 | 5,961 | 3,937 | | 3 | Profit/(loss) for the period | 2,906 | 1,743 | 5,941 | 3,776 | | 4 | Profit/(loss) attributable to ordinary equity holders of the parent | 2,906 | 1,743 | 5,941 | 3,776 | | 5 | Basic earnings/(loss) per share (Subunit) | 0.32 | 0.22 | 0.65 | 0.47 | | 6 | Proposed/Declared dividend per share (Subunit) | 0.00 | 0.00 | 0.00 | 0.00 |
|
| AS AT END OF CURRENT QUARTER | AS AT PRECEDING FINANCIAL YEAR END | 7
| Net assets per share attributable to ordinary equity holders of the parent ($$) | 0.3300 | 0.1700 |
|
|
|
|
|
|
|
|
|
|
|
|
发表于 31-5-2015 03:25 AM
|
显示全部楼层
[tr][/tr]EX-date | 09 Jun 2015 | Entitlement date | 11 Jun 2015 | Entitlement time | 05:00 PM | Entitlement subject | Bonus Issue | Entitlement description | Bonus issue of up to 599,760,718 warrants ("Bonus Warrants") on the basis of one (1) Bonus Warrant for every two (2) existing ordinary shares of RM0.10 each in TMC Life Sciences Berhad held at 5.00 p.m. on 11 June 2015 ("Entitlement Date"). | Period of interest payment | to | Financial Year End | 31 May 2016 | Share transfer book & register of members will be | to closed from (both dates inclusive) for the purpose of determining the entitlement | Registrar or Service Provider name, address, telephone no | TRICOR INVESTOR SERVICES SDN BHDLevel 17, The Gardens North TowerMid Valley City, Lingkaran Syed Putra59200 Kuala LumpurTel:03-22643883Fax:03-22821886 | Payment date |
| | a.Securities transferred into the Depositor's Securities Account before 4:00 pm in respect of transfers | 11 Jun 2015 | b.Securities deposited into the Depositor's Securities Account before 12:30 pm in respect of securities exempted from mandatory deposit |
| | c. Securities bought on the Exchange on a cum entitlement basis according to the Rules of the Exchange. | Number of new shares/securities issued (units) (If applicable) |
| | Entitlement indicator | Ratio | Ratio | 1 : 2 |
|
|
|
|
|
|
|
|
|
|
|
|
发表于 31-5-2015 05:06 AM
|
显示全部楼层
Date of change | 31 May 2015 | Name | Miss YAP ENG GEE | Age | 46 | Nationality | Malaysia | Type of change | Resignation | Designation | Chief Financial Officer | Reason | To pursue own interest |
Date of change | 01 Jun 2015 | Name | Mr JAMES OOI SIEW LOONG | Age | 48 | Nationality | Malaysia | Type of change | Appointment | Designation | Chief Financial Officer | Qualifications | Chartered Institute of Management Accountants, United KingdomMalaysian Institute of AccountantsMBA, Charles Stuart University, Australia | Working experience and occupation | Mr. James Ooi has over 20 years of experience in the areas of financial management in various industries with multinational corporations (MNCs) and local public listed companies. He has previously worked in senior positions at large organisations such as HSBC Bank Malaysia Berhad, Tropicana Corporation Berhad and Prudential Malaysia. |
|
|
|
|
|
|
|
|
|
|
|
|
发表于 3-6-2015 03:41 AM
|
显示全部楼层
本帖最后由 icy97 于 3-6-2015 11:53 PM 编辑
TMC 生科委执行董事
财经新闻 财经 2015-06-03 10:23
（吉隆坡2日讯）TMC生命科学（TMCLIFE，0101，主板贸服股）宣布，委任新加坡内政部副秘书郭鸿森（译音），作为执行董事。
根据文告，郭鸿森现年45岁，自1994年起为新加坡政府服务，曾担任新加坡国防部副总监、教育部总监、国家人口秘书处顾问和卫生部副秘书等。
TMC生命科学的主要业务，是提供助孕及妇科医疗服务。【南洋网财经】
Date of change | 02 Jun 2015 | Name | Mr ROY QUEK HONG SHENG | Age | 45 | Nationality | Singapore | Designation | Executive Director | Directorate | Executive | Type of change | Appointment | Qualifications | (1) Degree from London School of Economics & Political Science(2) Postgradute Degree from Peking University | Working experience and occupation | 2013-to date : Deputy Secretary, Ministry of Home Affairs2008-2013 : Deputy Secretary, Ministry of Health2008-2009 : Adviser, National Population Secretariat2006-2008 : Founding Director, National Population Secretariat, Prime Minister's Office2006-2007 : Director, Ministry of Community Development, Youth & Sports2003-2005 : Director, Ministry of Education1994-2002 : Deputy Director, Ministry of Defence |
|
|
|
|
|
|
|
|
|
|
|
|
发表于 24-6-2015 12:01 AM
|
显示全部楼层
Type | Announcement | Subject | TRANSACTIONS (CHAPTER 10 OF LISTING REQUIREMENTS)
RELATED PARTY TRANSACTIONS | Description | ACQUISITION | (Unless otherwise stated, all definitions and terms used in this announcement shall have the same meaning as defined in the announcement dated 6 February 2015).
We refer to the announcements dated 6 February 2015, 25 March 2015, 6 May 2015, 7 May 2015 and 28 May 2015 in relation to the Acquisition.
On behalf of the Board, Maybank IB wishes to announce that the Acquisition was completed on 23 June 2015 in accordance with the SPA. Accordingly the Company had on the same day allotted and issued the Consideration Shares and Consideration Warrants to the Vendor and its nominees as set out in Appendix I of this Announcement.
This Announcement is dated 23 June 2015. |
http://www.bursamalaysia.com/market/listed-companies/company-announcements/4781009
|
|
|
|
|
|
|
|
|
|
|
|
发表于 24-6-2015 11:54 PM
|
显示全部楼层
| 1. Details of Corporate Proposal | Involve issuance of new type/class of securities ? | No | Types of corporate proposal | Acquisitions | Details of corporate proposal | Acquisition | No. of shares issued under this corporate proposal | 533,333,333 | Issue price per share ($$) | Malaysian Ringgit (MYR) 0.7500 | Par Value ($$) | Malaysian Ringgit (MYR) 0.100 | | Latest issued and paid up share capital after the above corporate proposal in the following | Units | 1,732,854,769 | Currency | Malaysian Ringgit (MYR) 173,285,476.900 | Listing Date | 25 Jun 2015 |
|
|
|
|
|
|
|
|
|
|
|
|
发表于 25-6-2015 02:35 AM
|
显示全部楼层
Instrument Category | Securities of PLC | Instrument Type | Warrants | Description | (I) ACQUISITION BY TMC OF 1,000,000 ORDINARY SHARES OF RM1.00 EACH, REPRESENTING THE ENTIRE EQUITY INTEREST OF BB WATERFRONT SDN. BHD. FROM BEST BLEND SDN. BHD. FOR A PURCHASE CONSIDERATION OF RM400,000,000 SATISFIED VIA THE ISSUANCE OF 533,333,333 NEW ORDINARY SHARES OF RM0.10 EACH IN TMC ("SHARES" OR "TMC SHARES") ("CONSIDERATION SHARES") AT AN ISSUE PRICE OF RM0.75 PER SHARE, TOGETHER WITH 266,666,666 FREE DETACHABLE WARRANTS ("CONSIDERATION WARRANTS") ON THE BASIS OF ONE (1) CONSIDERATION WARRANT FOR EVERY TWO (2) CONSIDERATION SHARES; AND(II) BONUS ISSUE OF 599,760,718 WARRANTS ("BONUS WARRANTS") IN TMC TO ALL ENTITLED SHAREHOLDERS OF TMC ON THE BASIS OF ONE (1) BONUS WARRANT FOR EVERY TWO (2) EXISTING TMC SHARES HELD ON 11 JUNE 2015 |
Listing Date | 25 Jun 2015 | Issue Date | 23 Jun 2015 | Issue/ Ask Price | Not Applicable | Issue Size Indicator | Unit | Issue Size in Unit | 866,427,384 | Maturity | Mandatory | Maturity Date | 21 Jun 2019 | Revised Maturity Date |
| | Name of Guarantor | Not Applicable | Name of Trustee | Not Applicable | Coupon/Profit/Interest/Payment Rate | Not Applicable | Coupon/Profit/Interest/Payment Frequency | Not Applicable | Redemption | Not Applicable | Exercise/Conversion Period | 4.00 Year(s) | Revised Exercise/Conversion Period | Not Applicable | Exercise/Strike/Conversion Price | Malaysian Ringgit (MYR) 0.7500 | Revised Exercise/Strike/Conversion Price | Not Applicable | Exercise/Conversion Ratio | 1:1 | Revised Exercise/Conversion Ratio | Not Applicable | Mode of satisfaction of Exercise/ Conversion price | Cash | Settlement Type/ Convertible into | Physical (Shares) |
| Remarks : | | Each Warrant (collectively, the Consideration Warrant and Bonus Warrant) entitles the registered holder to subscribe for one new TMC Share at any time during the four (4) years period commencing on and including 23 June 2015 to the close of business at 5.00 p.m. on 21 June 2019 ("Exercise Period") at RM0.75 per new TMC Share subject to adjustments in accordance with the provisions of the deed poll dated 28 May 2015 constituting the Warrants.At the expiry of the Exercise Period, any Warrants which have not been exercised will lapse and cease to be valid for any purpose.This announcement is dated 24 June 2015. |
Announcement Info| Company Name | TMC LIFE SCIENCES BERHAD | | Stock Name | TMCLIFE-WB | | Date Announced | 24 Jun 2015 | | Category | Listing Information and Profile | | Reference Number | LIP-24062015-00009
|
|
|
|
|
|
|
|
|
|
|
|
|
发表于 25-6-2015 02:40 AM
|
显示全部楼层
Notice of Interest Sub. S-hldr (29A)Particulars of Substantial Securities HolderName | BEST BLEND SDN. BHD. | Address | 157A, Jalan Sri Pelangi
Taman Pelangi
Johor Bahru
80400 Johor
Malaysia. | NRIC/Passport No/Company No. | 919260-X | Nationality/Country of incorporation | Malaysia | Descriptions (Class & nominal value) | Ordinary Shares of RM0.10 each | Name & address of registered holder | Best Blend Sdn. Bhd.157A, Jalan Sri PelangiTaman Pelangi80400 Johor Bahru, Johor |
| Date interest acquired & no of securities acquired | Currency | Malaysian Ringgit (MYR) | Date interest acquired | 23 Jun 2015 | No of securities | 90,000,000 | Circumstances by reason of which Securities Holder has interest | Allotment of shares pursuant to the completion of the sale and purchase agreement entered into between Best Blend Sdn. Bhd. and TMC Life Sciences Berhad | Nature of interest | Direct interest | Price Transacted ($$) |
|  | | Total no of securities after change | Direct (units) | 90,000,000 | Direct (%) | 5.194 | Indirect/deemed interest (units) | 0 | Indirect/deemed interest (%) |
| | Date of notice | 24 Jun 2015 |
|
|
|
|
|
|
|
|
|
|
| |
 本周最热论坛帖子
|
2654 
75
